Follow us on Twitter
twitter icon@FreshPatents

Baclofen patents

Bulk PDF Downloads
      

This page is updated frequently with new Baclofen-related patent applications.




 Intravenous baclofen formulations and treatment methods patent thumbnailIntravenous baclofen formulations and treatment methods
An intravenous baclofen solution is disclosed, along with methods of dosing and treatment therewith.. .
Allaysis, Llc


 Composition comprising torasemide and baclofen for treating neurological disorders patent thumbnailComposition comprising torasemide and baclofen for treating neurological disorders
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of multiple sclerosis, alzheimer's disease, alzheimer's disease related disorders, amyotrophic lateral sclerosis, parkinson's disease, huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury..
Pharnext


 Intrathecal baclofen pharmaceutical dosage forms and related delivery system patent thumbnailIntrathecal baclofen pharmaceutical dosage forms and related delivery system
According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.. .
Mallinckrodt Llc


 Transdermal delivery kits patent thumbnailTransdermal delivery kits
Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine hcl, ibuprofen, lidocaine hcl, naproxen, and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens..
Asclemed Usa, Inc. Dba Enovachem Manufacturing


 Stable oral solutions for combined api patent thumbnailStable oral solutions for combined api
The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.. .
Pharnext


 Baclofen formulations and methods for making same patent thumbnailBaclofen formulations and methods for making same
Methods for preparing sterilized baclofen solutions include adjusting the ph to below a desired ph, and steam sterilizing the solution with adjusted ph, which results in the solution having the desired ph. Such solutions may also have low concentrations of 4-cpp.
Medtronic, Inc.


 Baclofen and acamprosate based therapy of neurological disorders patent thumbnailBaclofen and acamprosate based therapy of neurological disorders
The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of alzheimer's disease, alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, parkinson's disease, huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination..
Pharnext


 Method for administering omega-conopeptide patent thumbnailMethod for administering omega-conopeptide
The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.
Jazz Pharmaceuticals International Limited


 Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use patent thumbnailAnhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
Crystalline (3r)-4-{[(1s)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3r)-4-{[(1s)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.. .
Xenoport, Inc.


 Intrathecal baclofen pharmaceutical dosage forms and related delivery system patent thumbnailIntrathecal baclofen pharmaceutical dosage forms and related delivery system
According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.. .
Mallinckrodt Llc


Baclofen and acamprosate based therapy of macular degeneration disorders


The present invention relates to combinations and methods for the treatment of macular degeneration disorders. More specifically, the present invention relates to novel combinatorial therapies of age related macular degeneration based on baclofen and acamprosate combination..
Pharnext


Nootropic compositions for improving memory performance


The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory..
Pharnext


Methods for treating insomnia


Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia.
Lynn Health Science Institute, Inc.


Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products


The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time.
Mallinckrodt Llc


Transdermal delivery kits


Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine hcl, ibuprofen, lidocaine hcl, naproxen and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens..
Asclemed Usa, Inc. Dba Enovachem Manufacturing


Baclofen and acamprosate based therapy of neurological disorders


The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of alzheimer's disease, alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, parkinson's disease, huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination..
Pharnext


Method for administering omega-conopeptide


The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.
Jazz Pharmaceuticals International Limited


Therapeutic combination of memantine and baclofen and pharmaceutical composition containing them


The present invention relates to the combination of memantine and baclofen active ingredients, and also to the method for achieving body weight loss and thereby treating obesity and related co-morbidities by co-administration of baclofen and memantine.. .

Methods of administering drugs in an implantable multi-chamber pump


One embodiment of the present invention is a method for reducing pain using a multi chamber pump to separately administer multiple drugs. For example, one chamber may contain an omega conopeptide, such as ziconotide, and the other chamber or chambers may contain one or more other drugs, which may include of morphine, hydromorphone, fentanyl, sufentanil, bupivacaine, baclofen, clonidine, and buprenorphine, or their pharmaceutically acceptable salts thereof.

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Baclofen solution for low-volume therapeutic delivery


A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml.

Method for administering omega-conopeptide


The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.

Method of treating a disease condition susceptible to baclofen therapy


The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.. .

Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use


Crystalline (3r)-4-{[(1s)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3r)-4-{[(1s)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.. .

High concentration baclofen preparations


Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/ml up to about 10 mg/ml are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration.

Methods of treating autism


Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (gaba) can be a gaba(b) agonist, such as baclofen.

Method for administering omega-conopeptide


The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.

Zwitterion solution for low-volume therapeutic delivery


A formulation is provided that includes a volume of an aqueous multivalent physiological ion solution compatible with cerebrospinal fluid containing at least one divalent cation of magnesium or calcium, and at least one anion of carbonate or phosphate, and having a ph between 6.5 and 8.0. A zwitterionic therapeutic agent other than baclofen is dissolved the solution to achieve higher concentration or ease of solution and/or storage relative to therapeutic saline solutions of the same agent.

High concentration baclofen preparations


Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/ml up to about 10 mg/ml are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration.

Baclofen formulations and methods for making same


Methods for preparing sterilized baclofen solutions include adjusting the ph to below a desired ph, and steam sterilizing the solution with adjusted ph, which results in the solution having the desired ph. Such solutions may also have low concentrations of 4-cpp.

Pharmaceutical formulation for reducing pain


The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.

Baclofen and acamprosate based therapy of neurological disorders


The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of multiple sclerosis, alzheimer's disease, alzheimer's disease related disorder, amyotrophic lateral sclerosis, parkinson's disease, huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination..

Compounded transdermal pain management


The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously.

Baclofen and acamprosate based therapy of neurological disorders


The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of multiple sclerosis, alzheimer's disease, alzheimer's disease related disorder, amyotrophic lateral sclerosis, parkinson's disease, huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination..

Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use


Crystalline (3r)-4-{[(1s)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3r)-4-{[(1s)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.. .

Methods of treating autism


Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (gaba) can be a gaba(b) agonist, such as baclofen..

Methods of treating fragile x syndrome


Subjects having fragile x syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (gaba) can be a gaba(b) agonist, such as baclofen, including racemic and r-baclofen..



Baclofen topics:
  • Ziconotide
  • Hydromorphone
  • Buprenorphine
  • Intrathecal
  • Acamprosate
  • Spinal Cord Injury
  • Multiple Sclerosis
  • Spinal Cord
  • Butyric Acid
  • Sufentanil
  • Pharmaceutically Acceptable Salts
  • Bupivacaine
  • Antioxidant
  • Pharmaceutical Formulation
  • Pharmaceutically Acceptable Salt


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Baclofen for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Baclofen with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7096

    3299

    2 - 1 - 75